Dexcom inks new partnership to expand diabetes connected care

Dexcom and Health2Sync have forged a partnership aimed at reshaping diabetes care across Australia and Singapore, bringing Continuous Glucose Monitoring (CGM) into a broader digital chronic disease management ecosystem.

The deal comes as diabetes continues to impose a substantial burden on Australia’s health system. Almost 1.9 million Australians are living with diabetes, with more than 300 people diagnosed each day, the equivalent of one new diagnosis every five minutes.

Health2Sync operates a digital chronic disease management platform with about 1.7 million users across the region. The company has established a footprint in several Asian markets, providing digital tools intended to help people with diabetes and healthcare teams manage the demands of long-term care.

For Dexcom, the agreement adds another strand to an expanding digital-health strategy. The company partnered with Apple Watch last year to enable Australians using the Dexcom G7 CGM system to monitor glucose levels and receive alerts directly through their smartwatch. The Apple Watch integration allows Dexcom G7 users to view glucose levels in real time without carrying a smartphone or receiver, reflecting the company’s broader effort to make continuous monitoring less dependent on conventional hardware.

CGMs have transformed diabetes management by providing real-time glucose readings, trend data and alerts that help people make treatment decisions without relying solely on finger-prick testing.

Full or partial subsidisation is available for all people with type 1 diabetes and is provided by the Australian government through the National Diabetes Services Scheme (NDSS). In Aotearoa New Zealand, CGM is fully subsidised by Pharmac for people with type 1 diabetes. However, CGM access remains unsubsidised for people with type 2 diabetes in both countries, meaning that individuals in this group must self-fund the cost of the CGM.

The Health2Sync agreement gives Dexcom another strategic foothold in Asia-Pacific at a time when digital health companies are increasingly attempting to connect monitoring devices with software platforms used by patients and clinicians. Australia and Singapore are both pursuing greater use of remote monitoring and data-driven approaches to managing chronic conditions.

The companies, however, have not yet disclosed commercial terms or detailed the timeline for when an integrated offering could reach patients or healthcare providers.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.